Resveratrol attenuates endothelial oxidative injury by inducing autophagy via the activation of transcription factor EB.
Level 5 - mechanism / opinion, no new human data
In vitro laboratory study in human umbilical vein endothelial cells (HUVECs).
PubMed 31303889 · doi:10.1186/s12986-019-0371-6
What was done
Human umbilical vein endothelial cells (HUVECs) were pretreated with 10 μM resveratrol for 2 hours before exposure to 200 μM palmitic acid for 24 hours. Investigators evaluated cell viability, reactive oxygen species (ROS), and malondialdehyde (MDA) levels. Autophagosomes were imaged with transmission electron microscopy, and lysosomes were tracked with confocal microscopy. Transcription factor EB (TFEB) expression and downstream autophagy-related targets were quantified by qRT-PCR and western blot. Mechanistic dependence was tested using the autophagy inhibitor 3-methyladenine (3-MA) and TFEB small interfering RNA (siRNA) knockdown.
What was found
Resveratrol pretreatment suppressed the palmitic acid-induced drop in cell viability and reduced ROS and MDA accumulation. It promoted autophagosome formation, increased LC3 production, and accelerated P62 degradation; these autophagy markers were blocked by 3-MA. Resveratrol upregulated TFEB and downstream target genes in a concentration-dependent manner. TFEB siRNA knockdown abolished resveratrol-induced TFEB expression, autophagy activation, lysosome formation, and the observed antioxidant protection. The abstract reports directional effects without exact quantitative values, effect sizes, or p-values.
Why it matters
This study outlines a specific molecular mechanism (TFEB activation and subsequent autophagy induction) by which resveratrol protects endothelial cells from lipid-induced oxidative stress in vitro.
Limits
The study was conducted entirely in cultured HUVECs, which do not reflect in vivo hemodynamics, human metabolic clearance, or the low bioavailability of oral resveratrol. No quantitative metrics or sample sizes (number of replicates) were reported in the abstract. Clinical relevance to human atherosclerosis remains unproven.
Cited by
- supports Resveratrol induces genes regulated by TFEB to enhance lysosomal system capacity.